Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies

Research output: Contribution to journalArticle

Abstract

Background: Cisplatin-based chemotherapy remains the mainstay treatment for advanced lung cancer; however, it remains controversial whether the efficacy of chemotherapy can be modulated by the immune-checkpoint status. In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Methods: Among 91 patients who participated in the two aforementioned trials, those with assessable tumor specimens were included in this sub-analysis. PD-L1 expression levels were determined using immunohistochemical staining, while the Response Evaluation Criteria in Solid Tumors, version 1.1, were used for determining treatment efficacy. Results: Thirty-two patients were investigated. PD-L1 expression was observed in 8 patients (25.0%; the PD-L1-positive group), with 2 exhibiting a PD-L1 expression of 50% or more. None of the patients in the PD-L1-positive group responded to treatment, while the overall response rate in the PD-L1-negative group was 20.8% (5 of 24; P = 0.296). Both the progression-free survival and overall survival rates were worse in the PD-L1-positive group than in the PD-L1-negative group (3.7 vs. 5.9 months [P = 0.018] and 5.8 vs. 37.3 months [P = 0.070], respectively). Conclusion: PD-L1 expression was negatively correlated with survival in patients receiving cisplatin-based chemotherapy.

Original languageEnglish
JournalRespiratory Investigation
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Feasibility Studies
Cisplatin
Lung Neoplasms
Cell Death
Prospective Studies
Ligands
Drug Therapy
Disease-Free Survival
Survival Rate
Staining and Labeling
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Lung cancer
  • PD-L1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{1ea9b134bff24226ad64a49f1c370b99,
title = "Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies",
abstract = "Background: Cisplatin-based chemotherapy remains the mainstay treatment for advanced lung cancer; however, it remains controversial whether the efficacy of chemotherapy can be modulated by the immune-checkpoint status. In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Methods: Among 91 patients who participated in the two aforementioned trials, those with assessable tumor specimens were included in this sub-analysis. PD-L1 expression levels were determined using immunohistochemical staining, while the Response Evaluation Criteria in Solid Tumors, version 1.1, were used for determining treatment efficacy. Results: Thirty-two patients were investigated. PD-L1 expression was observed in 8 patients (25.0{\%}; the PD-L1-positive group), with 2 exhibiting a PD-L1 expression of 50{\%} or more. None of the patients in the PD-L1-positive group responded to treatment, while the overall response rate in the PD-L1-negative group was 20.8{\%} (5 of 24; P = 0.296). Both the progression-free survival and overall survival rates were worse in the PD-L1-positive group than in the PD-L1-negative group (3.7 vs. 5.9 months [P = 0.018] and 5.8 vs. 37.3 months [P = 0.070], respectively). Conclusion: PD-L1 expression was negatively correlated with survival in patients receiving cisplatin-based chemotherapy.",
keywords = "Chemotherapy, Cisplatin, Lung cancer, PD-L1",
author = "Kazuya Nishii and Katsuyuki Hotta and Kiichiro Ninomiya and Yuka Kato and Eiki Ichihara and Kadoaki Ohashi and Takashi Ninomiya and Toshio Kubo and Kammei Rai and Masahiro Tabata and Yoshinobu Maeda and Katsuyuki Kiura",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.resinv.2019.04.004",
language = "English",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer

T2 - A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies

AU - Nishii, Kazuya

AU - Hotta, Katsuyuki

AU - Ninomiya, Kiichiro

AU - Kato, Yuka

AU - Ichihara, Eiki

AU - Ohashi, Kadoaki

AU - Ninomiya, Takashi

AU - Kubo, Toshio

AU - Rai, Kammei

AU - Tabata, Masahiro

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Cisplatin-based chemotherapy remains the mainstay treatment for advanced lung cancer; however, it remains controversial whether the efficacy of chemotherapy can be modulated by the immune-checkpoint status. In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Methods: Among 91 patients who participated in the two aforementioned trials, those with assessable tumor specimens were included in this sub-analysis. PD-L1 expression levels were determined using immunohistochemical staining, while the Response Evaluation Criteria in Solid Tumors, version 1.1, were used for determining treatment efficacy. Results: Thirty-two patients were investigated. PD-L1 expression was observed in 8 patients (25.0%; the PD-L1-positive group), with 2 exhibiting a PD-L1 expression of 50% or more. None of the patients in the PD-L1-positive group responded to treatment, while the overall response rate in the PD-L1-negative group was 20.8% (5 of 24; P = 0.296). Both the progression-free survival and overall survival rates were worse in the PD-L1-positive group than in the PD-L1-negative group (3.7 vs. 5.9 months [P = 0.018] and 5.8 vs. 37.3 months [P = 0.070], respectively). Conclusion: PD-L1 expression was negatively correlated with survival in patients receiving cisplatin-based chemotherapy.

AB - Background: Cisplatin-based chemotherapy remains the mainstay treatment for advanced lung cancer; however, it remains controversial whether the efficacy of chemotherapy can be modulated by the immune-checkpoint status. In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Methods: Among 91 patients who participated in the two aforementioned trials, those with assessable tumor specimens were included in this sub-analysis. PD-L1 expression levels were determined using immunohistochemical staining, while the Response Evaluation Criteria in Solid Tumors, version 1.1, were used for determining treatment efficacy. Results: Thirty-two patients were investigated. PD-L1 expression was observed in 8 patients (25.0%; the PD-L1-positive group), with 2 exhibiting a PD-L1 expression of 50% or more. None of the patients in the PD-L1-positive group responded to treatment, while the overall response rate in the PD-L1-negative group was 20.8% (5 of 24; P = 0.296). Both the progression-free survival and overall survival rates were worse in the PD-L1-positive group than in the PD-L1-negative group (3.7 vs. 5.9 months [P = 0.018] and 5.8 vs. 37.3 months [P = 0.070], respectively). Conclusion: PD-L1 expression was negatively correlated with survival in patients receiving cisplatin-based chemotherapy.

KW - Chemotherapy

KW - Cisplatin

KW - Lung cancer

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85067045576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067045576&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2019.04.004

DO - 10.1016/j.resinv.2019.04.004

M3 - Article

C2 - 31186170

AN - SCOPUS:85067045576

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

ER -